These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 7755488)
21. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395 [No Abstract] [Full Text] [Related]
22. Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome. Sidransky H; Verney E; Latham P; Schwartz A Adv Exp Med Biol; 1996; 398():343-50. PubMed ID: 8906287 [No Abstract] [Full Text] [Related]
23. Endogenous formation of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3- carboxylic acid in man as the possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Adachi J; Yamamoto K; Ogawa Y; Ueno Y; Mizoi Y; Tatsuno Y Arch Toxicol; 1991; 65(6):505-9. PubMed ID: 1929872 [TBL] [Abstract][Full Text] [Related]
24. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico. Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958 [TBL] [Abstract][Full Text] [Related]
25. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis. Varga J; Jimenez SA; Uitto J J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409 [TBL] [Abstract][Full Text] [Related]
26. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Simat TJ; Kleeberg KK; Müller B; Sierts A Adv Exp Med Biol; 1999; 467():469-80. PubMed ID: 10721090 [TBL] [Abstract][Full Text] [Related]
27. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Klarskov K; Johnson KL; Benson LM; Gleich GJ; Naylor S Adv Exp Med Biol; 1999; 467():461-8. PubMed ID: 10721089 [TBL] [Abstract][Full Text] [Related]
28. On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome. Williamson BL; Johnson KL; Tomlinson AJ; Gleich GJ; Naylor S Toxicol Lett; 1998 Oct; 99(2):139-50. PubMed ID: 9817085 [TBL] [Abstract][Full Text] [Related]
29. Comparative studies on tryptophan binding to hepatic nuclear envelopes in Sprague-Dawley and Lewis rats. Sidransky H; Verney E Am J Physiol; 1994 Aug; 267(2 Pt 2):R502-7. PubMed ID: 8067461 [TBL] [Abstract][Full Text] [Related]
30. Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome. Klarskov K; Gagnon H; Boudreault PL; Normandin C; Plancq B; Marsault E; Gleich GJ; Naylor S Toxicol Lett; 2018 Jan; 282():71-80. PubMed ID: 29037509 [TBL] [Abstract][Full Text] [Related]
31. Review of L-tryptophan and eosinophilia-myalgia syndrome. Roufs JB J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654 [TBL] [Abstract][Full Text] [Related]
32. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622 [TBL] [Abstract][Full Text] [Related]
33. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro. Zangrilli JG; Mayeno AN; Vining V; Varga J Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499 [TBL] [Abstract][Full Text] [Related]
34. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome. Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716 [TBL] [Abstract][Full Text] [Related]
35. Contaminants in biotechnologically manufactured L-tryptophan. Simat T; van Wickern B; Eulitz K; Steinhart EH J Chromatogr B Biomed Appl; 1996 Oct; 685(1):41-51. PubMed ID: 8930752 [TBL] [Abstract][Full Text] [Related]
37. [A case of the eosinophilia-myalgia syndrome]. Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794 [TBL] [Abstract][Full Text] [Related]
38. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique. Shapiro S J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181 [TBL] [Abstract][Full Text] [Related]
39. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. Michelson D; Page SW; Casey R; Trucksess MW; Love LA; Milstien S; Wilson C; Massaquoi SG; Crofford LJ; Hallett M J Rheumatol; 1994 Dec; 21(12):2261-5. PubMed ID: 7699627 [TBL] [Abstract][Full Text] [Related]
40. Eosinophilia-myalgia syndrome in patients ingesting a single source of L-tryptophan. Henning KJ; Jean-Baptiste E; Singh T; Hill RH; Friedman SM J Rheumatol; 1993 Feb; 20(2):273-8. PubMed ID: 8474064 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]